Abstracts tagged "Infection"

Abstract Number: 0414 • ACR Convergence 2024
Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis
Andrew Grim¹, Yongdong (Dan) Zhao², Christine Wang¹, Erin Janssen³, Jessica Turnier⁴, Anastasia Hyrhorczuk¹ and Nadine Saad¹, ¹University of Michigan, Ann Arbor, MI, ²University of Washington, Redmond, WA, ³CS Mott Children's Hospital, Ann Arbor, MI, ⁴University of Michigan, Saline, MI
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder. Some patients with CNO may present acutely and be misdiagnosed as infectious osteomyelitis (IO).…
Abstract Number: 1509 • ACR Convergence 2024
Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Rosana Quintana¹, Guillermo Pons-Estel², Karen Roberts³, Erika S. Palacios Santillan³, Íñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Pablo Ibañez⁶, Leonel Ariel Berbotto⁷, Maria Constanza Bertolaccini⁸, Marina Laura Micelli⁹, Cecilia Pisoni¹⁰, Vitalina De Souza Barbosa¹¹, Henrique de Ataíde Mariz¹², Francinne Machado Ribeiro¹³, Luciana Parente¹⁴, Emília Sato¹⁵, Milena Mimica Davet¹⁶, Gustavo Aroca Martínez¹⁷, Fabio Bonilla-Abadía¹⁸, Gerardo Quintana López¹⁹, Reyna E. Sánchez Briones²⁰, Mario Pérez Cristóbal²¹, Luis H. Silveira Torre²², Ignacio García De La Torre²³, Ivan Morales Avendaño²⁴, Pablo Gamez-Siller²⁵, Astrid Paats²⁶, Jorge N. Cieza Calderón²⁷, Andy Armando Mendoza Maldonado²⁸, Martin Rebella²⁹, Gonzalo Silveira³⁰, John Fredy Jaramillo³¹, Monica Sanchez³², Urbano Sbarigia³³, Ashley Orillion³⁴, Federico Zazzetti³⁵, Graciela Alarcon³⁶ and Bernardo Pons-Estel³⁷, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ³Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁵Galicia Health Service (SERGAS), Vigo, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Planta, Argentina, ⁷Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ⁸Servicio de Reumatologia - Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina, ⁹Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, ¹⁰CEMIC, Buenos Aires, Argentina, ¹¹Hospital das Clínicas, Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹²Universidad Federal de Pernambuco, Recife, Brazil, ¹³Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ¹⁶Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ¹⁷Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ²¹Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ²²Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ²³Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, ²⁴Hospital Central Dr. Ignacio Morones Prieto, Potosi, Mexico, ²⁵Servicio de Reumatologia del Hospital Universitario, "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²⁶Hospital de Clínicas I, Asunción, Paraguay, ²⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Perú, Lima, Peru, ²⁸Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁹Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ³⁰Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Unidad Nefrologia,Hospital fernandez, CABA, Argentina, ³³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³⁴Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁵Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁶The University of Alabama at Birmingham, Oakland, CA, ³⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of serious infections, which in turn, are associated with morbidity and mortality. The Systemic…
Abstract Number: 2613 • ACR Convergence 2024
Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Emily Kowalski³, Xiaosong Wang⁴, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni⁴, Caleb Bolden⁵, Naomi Patel⁵, Krishan Guzzo³, Marcy Bolster⁵, Shruthi Srivatsan⁵, Pierre-Antoine Juge⁶, Tracy J Doyle⁷, Zachary Wallace⁸ and Jeffrey Sparks⁹, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA, ⁸Massachusetts General Hospital, Newton, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…
Abstract Number: 0248 • ACR Convergence 2024
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
Nadia Aikawa¹, Ana Cristina Medeiros-Ribeiro², Sandra Pasoto³, Leonard Kupa³, Luciana Seguro⁴, ANA PAULA ASSAD³, Eduardo Borba³, Carla Goncalves Schahin Saad⁴, Emily Figueiredo Neves Yuki³, Danieli Andrade⁵, Andrea Shimabuco⁴, Karina Bonfiglioli³, Diogo Domiciano³, Julio Moraes³, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Henrique Giardini³, Joao de Oliveira³, Isabele Antonelli³, Renata Pinheiro³, Thais Bonini³, Marta Lopes⁶, Clovis Silva⁷ and Eloisa Bonfa³, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
Abstract Number: 0513 • ACR Convergence 2024
Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting
Ioasaf Karafotias¹, Maryam Adas¹, Katie Bechman¹, Nicholas Williamson¹, Mark Hughes¹, Daksh Mehta², Ritika Roy¹, Sam Norton³ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, England, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
Abstract Number: 1519 • ACR Convergence 2024
Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Chunhui Chen¹, Emily Wu², Huong Do³ and Kyriakos Kirou³, ¹New York Presbyterian Queens, Flushing, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
Abstract Number: 2614 • ACR Convergence 2024
Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Ana Milena Gil¹, Julián Barahona-Correa², Jorge Bruce Flórez-Suárez³, Daniel Fernández-Ávila⁴ and Zulma Cucunubá¹, ¹Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia, ²Division of Rheumatology, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia, ³Department of Immunology, Universidad Nacional de Colombia, Bogotá, Colombia, ⁴5Hospital San Ignacio, Colombia, BOGOTA, Colombia
Background/Purpose: The association between SARS-CoV-2 infection and the new onset of immune-mediated diseases is a topic of interest given the conflicting evidence available. This systematic…
Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 0680 • ACR Convergence 2023
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Johanne LIBERATORE¹, Yann Nguyen², Jerome HADJADJ³, Pascal Cohen⁴, Luc Mouthon⁵, Xavier Puéchal⁶, Loic Guillevin⁷ and Benjamin Terrier⁸, ¹Centre Hospitalier ANGOULEME, Angouleme, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Cochin Hospital, Paris, France, ⁴CHU Cochin, Paris, France, ⁵Hopital Cochin - Paris University, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁷University Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels…
Abstract Number: 1445 • ACR Convergence 2023
SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort
Iñigo Rúa-Figueroa¹, Maria Jesus Garcia de Yebenes², JULIA MARTINEZ BARRIO³, Maria Galindo-Izquierdo⁴, Jaime Calvo- Alén⁵, Antonio Fernandez-Nebro⁶, Raúl Menor-Almagro⁷, Eva Tomero Muriel⁸, Mercedes Freire González⁹, Clara Sanguesa Gomez¹⁰, Loreto Horcada¹¹, Ricardo Blanco¹², Esther Uriarte Isacelaya¹³, Maria J. García-Villanueva¹⁴, Javier Narvaez¹⁵, Jose Rosas¹⁶, Silvia Gómez-Sabater¹⁷, Clara Moriano Morales¹⁸, Jose Luis Andreu-Sánchez¹⁹, Vicente Torrente-Segarra²⁰, Elena Aurrecoechea Aguinaga²¹, Ana Pérez Gómez²², Javier Novoa Medina²³, Eva Salgado-Pérez²⁴, Nuria Lozano Rivas²⁵, Carlos Montilla-Morales²⁶, maria esther ruiz-lucea²⁷, Marta Arévalo Salaet²⁸, Carlota Iñíguez²⁹, Lorena Expósito³⁰, Mónica Ibáñez-Barceló³¹, Gema Bonilla³², Irene Carrión-Barberà³³, Celia Erausquin³⁴, Angela Pecondon-Español³⁵, Francisco Javier Toyos Sáenz de Miera³⁶, Tatiana Cobo³⁷, Alejandro Muñoz³⁸, Jorge Juan Fragio³⁹, Jose Eloy Oller⁴⁰, Beatriz Tejera Segura²³ and Jose-Maria Pego-Reigosa⁴¹, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²InMusc, Madrid, Spain, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁰Severo Ochoa Hospital, Madrid, Spain, ¹¹Hospital de Navarra, Pamplona, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁸Rheumatology, Hospital Universitario de León, León, Spain, ¹⁹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁰Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²¹Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²³Complejo Hospitalario Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁴Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ²⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁶Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²⁷Hospita de Basurto, Bilbao, Spain, ²⁸Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ²⁹Hospital Lucus Augusti, Lugo, Spain, ³⁰Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³¹Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ³²Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁵Hospital Miguel Servet, Zaragoza, Spain, ³⁶Hospital Virgen Macarena, Sevilla, Spain, ³⁷Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ³⁸Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁹Hospital General Universitario Valencia, Valencia, Spain, ⁴⁰Hospital Doctor Peset, Valencia, Spain, ⁴¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of serious infections that varies with the severity of the disease, use of immunosuppressives,…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 2316 • ACR Convergence 2023
Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study
Chi Chiu Mok¹, Chris Cheung², Chi Hung To³, Kar Li Kelly Chan⁴ and SAU MEI TSE⁵, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Rutonjee Hospital, Hong Kong, Hong Kong, ³Pok Oi Hospital, Hong Kong, Hong Kong, ⁴Tuen Mun Hospital, Shatin, China, ⁵Tuen Mun Hospital, Hong Kong, China
Background/Purpose: To study the effect of SARS-CoV2 infection on disease flares in patients with systemic lupus erythematosus (SLE).Methods: Patients who fulfilled the ACR or SLICC…
Abstract Number: 0206 • ACR Convergence 2023
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Akhil Sood, Janice Lin and Neha Shah, Stanford University, Palo Alto, CA
Background/Purpose: Due to the use of immunosuppressants, patients with rheumatic diseases are at increased risk for Hepatitis B virus (HBV) reactivation. B-cell depleting agents and…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 1479 • ACR Convergence 2023
Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Tiphaine Goulenok¹, Valentine Marie Ferre², Celine Mendes¹, Lea Dayan³, Margot Bucau¹, Fatima Farhi¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France, ³Maison de Sante les Epinettes, Paris, France
Background/Purpose: An impaired clearance of cervical human papillomavirus (HPV) related to inadequate immune responses may result in persistent infection and increase the risk to develop…

« Previous Page
1
…
6
7
8
9
10
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].